CMPI.org

Donors

At the Center for Medicine in the Public Interest, we acknowledge the generosity of our donors and their dedication to our mission and the advancement of healthcare policy.

AbbVie Inc.

Amicus Therapeutics

APCO Worldwide

Aprecia Pharmaceuticals

BIO

Bristol Myers Squibb

ChromaDex

Ewing Marion Kauffman Foundation

Gilead Sciences, Inc.

GSK

Juul Labs

The Lilly Foundation

Merck & Co.

National Community Pharmacists Association

Novo Nordisk Inc.

Pfizer, Inc.

PhRMA

Sarepta Therapeutics

Searle Freedom Trust

Stand Together Trust

Standup4Nurses

RECENT NEWS

The Journal of Clinical Investigation
08/17/2026 12:00 AM

New JCI Viewpoint: FDA Must Rethink How It Evaluates Precision Medicines for Rare Diseases

Authors argue that rare disease innovation requires learning more from fewer patients—not enrolling more patients... Read more

CMPI
10/14/2026 12:00 AM

Qualifying Single-Source Drug Policy, Medicare Price Negotiation, and the Incentives for Meaningful Post-Approval Innovation

CMS should demand evidence from manufacturers and be prepared to defend its own assumptions about innovation. Its next st... Read more

CMPI
08/10/2026 12:00 AM

Troubling Trends: Systemic Practices in Texas' Non-Profit Hospitals That Inflate Health Care Costs

Texas has an opportunity to lead rather than react. Better measurement would strengthen public confidence without diminis... Read more

Read all News

Donors

RECENT NEWS

New JCI Viewpoint: FDA Must Rethink How It Evaluates Precision Medicines for Rare Diseases

Qualifying Single-Source Drug Policy, Medicare Price Negotiation, and the Incentives for Meaningful Post-Approval Innovation

Troubling Trends: Systemic Practices in Texas' Non-Profit Hospitals That Inflate Health Care Costs

DRUGWONKS BLOG

RESEARCH ISSUES